Parker Waichman LLP Headlines by Topic
Bisphosphonates
Bisphosphonates May be Less Effective in Preventing Fractures after Five Years
May 10, 2012
| Parker Waichman LLP
A new study published in the New England Journal of Medicine is raising new concerns about the efficacy of long-term bisphosphonate therapy. ...
Conflicting Bisphosphonate Studies Raise Esophageal Cancer Worries
May 3, 2012
| Parker Waichman LLP
In 2010, two studies on oral bisphosphonates reached differing conclusions regarding the drugs’ association with an increased risk of...
Long-Term Bisphosphonate Side Effects May Include Esophageal Cancer
Apr 3, 2012
| Parker Waichman LLP
Evidence continues to mount that long-term use of oral bisphosphonates, including Fosamax, could lead to serious consequences continues to...
Parker Waichman Files 3 Dozen Fosamax Lawsuits on Single Day
Mar 15, 2012
| Parker Waichman LLP
Parker Waichman LLP has filed three dozen lawsuits on behalf of women who allegedly suffered Fosamax femur fractures after using the bisphosphonate...
Health Canada Revises Bisphosphonate Labels with Fracture Warning
Dec 20, 2011
| Parker Waichman LLP
Health Canada has announced that its review of bisphosphonates has shown a slightly increased risk of atypical thigh fractures among people who use...
FDA Panel Calls for New Warnings on Bisphosphonates, But Not Specific Time Limits on Usage
Sep 12, 2011
| Parker Waichman LLP
A panel of outside medical experts was unable to recommend how long women can safely take oral bisphosphonates for osteoporosis, but did vote 17-6...
Bisphoshonate Benefits Plateau at Five Years, FDA Says
Sep 8, 2011
| Parker Waichman LLP
Women who take oral bisphosphonates such as Fosamax to prevent broken bones from osteoporosis may not have to take them beyond five years to get...
Fosamax, Bisphosphonates Face FDA Review
Sep 6, 2011
| Parker Waichman LLP
A U.S. Food & Drug Administration (FDA) advisory panel scheduled to meet on Friday could recommend that women taking Fosamax and other oral...
FDA Boosts Reclast Kidney Failure Warnings
Sep 2, 2011
| Parker Waichman LLP
The osteoporosis drug Reclast (zoledronic acid) raises the risk of kidney failure in patients with a history of or risk factors for renal impairment,...
FDA: No Conclusion on Oral Bisphosphonate-Esophageal Cancer Link
Jul 21, 2011
| Parker Waichman LLP
The U.S. Food & Drug Administration (FDA) is reviewing a possible association between oral bisphosphonates and the development of esophageal...
